72 research outputs found
Effects of Amendments to H-2A Rules on Use of H-2A Program in Tobacco Growing States
Agricultural and Food Policy,
Exits Among U.S. Burley Tobacco Growers After the End of the Federal Tobacco Program
This study explores the relationship between family/farm characteristics and the probability of exiting burley tobacco farming in Tennessee, North Carolina, and Virginia. Following the termination of the federal tobacco program in 2004, 54% of burley tobacco–growing households in Tennessee, North Carolina, and Virginia exited burley tobacco farming by 2006. Tobacco yield, tobacco farm cash receipts, tobacco price, off-farm employment, and farm size are the most dominant variables discriminating between exiting and surviving tobacco farms. Data for this study came from a mail survey of burley tobacco producers in Tennessee, Virginia, and North Carolina in May 2006.burley tobacco, exit, federal tobacco program, Agribusiness, Agricultural and Food Policy, Crop Production/Industries, Environmental Economics and Policy, Financial Economics, Land Economics/Use, Risk and Uncertainty, C25, Q12, Q18,
Genetics, Insurance and Professional Practice: Survey of the Australasian Clinical Genetics Workforce
In Australia and New Zealand, by contrast with much of the developed world, insurance companies can use genetic test results to refuse cover or increase premiums for mutually-rated insurance products, including life, income protection and disability insurance. Genetics professionals regularly discuss insurance implications with clients and report the issue as a clinical challenge, yet no studies have examined clinical practices or opinions. This study surveyed genetic counsellors and clinical geneticists from Australia and New Zealand to (i) investigate variability in professional practice across the Australasian clinical genetic workforce relating to the insurance implications of genetic testing, and (ii) ascertain views regarding current regulation of the issue. There was considerable variability in training and clinical policies, especially around the communication of insurance implications. Almost half of participants reported receiving no training on the insurance implications of genetic testing, and almost 40% were unsure whether they could adequately advise clients. A number of deficits in professional knowledge and understanding of the issue were identified. Widespread concerns regarding regulation of this area were reported, with < 10% of Australian participants considering current Australian regulations as adequate to protect clients from genetic discrimination. The findings from this study highlight scope for greater education, consistency and professional training on the issue of genetics and insurance in Australasia, and strong agreement about the need for regulatory reform
Combined population genomic screening for three high-risk conditions in Australia: a modelling study
BACKGROUND:
No previous health-economic evaluation has assessed the impact and cost-effectiveness of offering combined adult population genomic screening for mutliple high-risk conditions in a national public healthcare system.
METHODS:
This modeling study assessed the impact of offering combined genomic screening for hereditary breast and ovarian cancer, Lynch syndrome and familial hypercholesterolaemia to all young adults in Australia, compared with the current practice of clinical criteria-based testing for each condition separately. The intervention of genomic screening, assumed as an up-front single cost in the first annual model cycle, would detect pathogenic variants in seven high-risk genes. The simulated population was 18–40 year-olds (8,324,242 individuals), modelling per-sample test costs ranging AU1200 (base-case AU200 per-test, genomic screening would require an investment of AU23,926 (∼£12,050/€14,110/US4758/QALY was obtained. Sensitivity analysis for the base case indicated that combined genomic screening would be cost-effective under 70% of simulations, cost-saving under 25% and not cost-effective under 5%. Threshold analysis showed that genomic screening would be cost-effective under the AU325 (∼£164/€192/US$208).
INTERPRETATION:
Our findings suggest that offering combined genomic screening for high-risk conditions to young adults would be cost-effective in the Australian public healthcare system, at currently realistic testing costs. Other matters, including psychosocial impacts, ethical and societal issues, and implementation challenges, also need consideration.
FUNDING:
Australian Government, Department of Health, Medical Research Future Fund, Genomics Health Futures Mission (APP2009024). National Heart Foundation Future Leader Fellowship (102604)
Genetic research: the role of citizens, public health and international stakeholders
Background: Genetic research has become an indispensable instrument for medical research, and the subjects involved have both divergent and convergent interests. Objective: The possibility of having more detailed genetic information undoubtedly offers benefits for the health of the subject, but could also pose risks and make the subject vulnerable to discrimination. Methods: The scientific community has viewed very favorably the public health utility of family history, in which data from a family whose members suffer from chronic pathologies is collected and filed, in order to develop a sort of “stratification of family risk.” Even though in the last decade the scientific and juridical literature has contributed greatly to the topic of biobanks, the perplexities that continue to surround this theme give the idea that current ethical protocols on research are inadequate. Results: Researchers, citizens, International stakeholders, mass media, Public Health and Governments play a key role in genetic research. It is obvious that the methods used for genetic research do not present intrinsic risks; they are much less dangerous than other activities of diagnosis and research. Before authorizing a research project, it is important to reflect on the responsibility and transparency of the studies to be conducted, and on the impact they may have on the interests of public health. Conclusion: We believe that the highest priority need is to develop a common language on the theme, as is the case in the sphere of clinical experimentation where rules of good clinical practice, albeit at times conflicting, have led to uniform convergences in the scientific world on the points to be actuated
- …